

Beyond the Headlines




Generic medicines reimbursement - monthly insights

Accord UK highlights key data to provide context into the trends that have impacted generic medicine reimbursement.

Concessions: July 2023


This chart demonstrates the gap between concession value and tariff, for concessionary products, and how that has changed over the past two years. It also shows the variation in the number of published price concessions over the same period.




Average reimbursement price (inc concession pricing)*



Full picture




Monthly generic medicines tariff value (inc concessions)*



Impact of the July product additions

The addition of 14 new products to the July Category M tariff has had a noticeable impact on the overall average reimbursement price. The most significant addition is Apixaban 2.5mg & 5mg Tablets, which moved across from Category C. As demonstrated below, you can see that if this product were to be removed from the figures, the average reimbursement price would decrease from £3.37 to £3.05 for July.



There has been a slight increase in overall base tariff from June to July which is mainly due to the other new product additions, including Sitagliptin 25mg, 50mg & 100mg Tablets. There is also a slight decrease in the concessionary figure from June, with fewer products/lower values for July.

Based on our calculations, Apixaban has had an overall monthly reimbursement decrease of around £7.3m now it has moved into Category M, compared to its previous Category C reimbursement pricing. As an annualised figure this would equate to almost £88m.

Keep an eye on future editions of Beyond the Headlines, where we will continue to track the Apixaban impact against new releases of the Category M tariff.

* Category A & M data used